LETTER TO THE EDITOR

Obese COVID-19 patients show more severe pneumonia lesions on CT chest imaging

The COVID-19 epidemic will persist for the foreseeable future. Given the significant toll the outbreak has taken on the healthcare system, identifying those patients with a greater need for medical attention is necessary. Recent studies suggest that obesity is associated with worse severity of COVID-19 pneumonia, increasing the need for hospitalization, critical care and mechanical ventilation.1–6

| TABLE 1 | Demographics, medical history, laboratory and pneumonia involvement (mm³) for the four BMI groups |
| Variables | Normal weight (n = 84, 36.4%) | Overweight (n = 105, 45.4%) | Obese (n = 33, 14.3%) | Underweight (n = 9, <0.1%) | F/χ² value | P |
| Age, years | 43.1 ± 14.2 | 47.7 ± 12.0 | 44.8 ± 13.3 | 49.1 ± 13.7 | 2.2 | .1 |
| Female/male patients (%) | 39/45 (46.4) | 43/62 (41.0) | 9/24 (27.3) | 3/6 (33.3) | 3.8 | .3 |
| Onset to hospitalization, days | 6.8 ± 6.2 | 7.0 ± 6.4 | 6.0 ± 6.1 | 6.9 ± 5.7 | 0.2 | .9 |
| Diabetes, yes/no (%) | 5/79 (6.0) | 6/99 (5.7) | 1/32 (3.0) | 1/8 (11.1) | 0.9 | .6 |
| Hypertension, yes/no (%) | 8/76 (9.5) | 15/90 (16.6) | 4/29 (13.8) | 0/9 (0) | 2.3 | .7 |
| Cardiovascular disease, yes/no (%) | 1/83 (1.2) | 3/102 (2.9) | 0/33 (0) | 0/9 (0) | 1.7 | .5 |
| Hyperlipidaemia, yes/no (%) | 0/84 (0) | 1/104 (1.0) | 2/31 (6.5) | 0/9 (0) | 7.2 | .1 |
| Liver disease, yes/no (%) | 3/81 (3.6) | 2/103 (1.9) | 0/33 (0) | 0/9 (0) | 1.7 | .2 |
| Cancer, yes/no (%) | 1/83 (1.2) | 1/104 (1.0) | 0/33 (0) | 0/9 (0) | 0.5 | .5 |
| Lung-related disease, yes/no (%) | 2/82 (2.4) | 1/104 (1.0) | 1/32 (3.0) | 0/9 (0) | 1.1 | .5 |
| C-reactive protein, mg/L | 13.1 ± 22.4 | 20.5 ± 23.8 | 30.1 ± 29.0 | 18.7 ± 22.7 | 4.1 | .01 |
| Whole lung, mm³ | | | | | | |
| Total lesion | 99.4 ± 142.9 | 193.9 ± 267.9 | 251.3 ± 348.6 | 191.7 ± 220.3 | 3.9 | .01 |
| Whole GGO | 76.7 ± 117.0 | 146.1 ± 205.1 | 192.1 ± 259.2 | 173.5 ± 210.3 | 3.9 | .01 |
| Whole consolidation | 22.6 ± 37.1 | 47.8 ± 76.8 | 59.2 ± 111.1 | 18.2 ± 20.4 | 3.2 | .02 |
| Right superior lobe, mm³ | | | | | | |
| Total lesion | 8.6 ± 29.2 | 32.2 ± 81.2 | 48.0 ± 86.2 | 19.6 ± 34.8 | 3.4 | .02 |
| GGO | 7.5 ± 26.6 | 25.8 ± 65.5 | 36.6 ± 63.4 | 18.7 ± 33.1 | 3.0 | .03 |
| Consolidation | 1.1 ± 3.8 | 6.3 ± 20.5 | 11.4 ± 27.7 | 0.9 ± 1.8 | 3.2 | .02 |
| Right middle lobe, mm³ | | | | | | |
| Total lesion | 3.0 ± 10.6 | 7.4 ± 19.7 | 11.9 ± 21.3 | 1.8 ± 2.4 | 2.7 | .05 |
| GGO | 2.6 ± 9.2 | 6.4 ± 17.3 | 10.0 ± 17.4 | 1.7 ± 2.3 | 2.5 | .06 |
| Consolidation | 0.3 ± 1.7 | 1.0 ± 3.1 | 1.9 ± 4.9 | 0.1 ± 0.1 | 2.4 | .07 |
| Right inferior lobe (mm³) | | | | | | |
| Total lesion | 42.1 ± 62.0 | 69.8 ± 94.2 | 90.8 ± 113.7 | 85.6 ± 96.6 | 3.2 | .03 |
| GGO | 31.6 ± 48.0 | 48.7 ± 65.8 | 68.5 ± 82.7 | 72.4 ± 80.3 | 3.4 | .02 |
| Consolidation | 10.5 ± 20.1 | 21.1 ± 34.2 | 22.4 ± 40.4 | 13.3 ± 19.6 | 2.3 | .08 |
| Left superior lobe, mm³ | | | | | | |
| Total lesion | 9.5 ± 24.5 | 27.0 ± 55.0 | 39.6 ± 72.4 | 23.6 ± 38.0 | 3.6 | .01 |
| GGO | 7.9 ± 21.9 | 22.2 ± 45.8 | 32.9 ± 60.5 | 23.1 ± 37.5 | 3.3 | .01 |
| Consolidation | 1.6 ± 4.3 | 4.7 ± 12.9 | 6.7 ± 16.7 | 0.5 ± 0.5 | 2.4 | .07 |
| Left inferior lobe, mm³ | | | | | | |
| Total lesion | 36.1 ± 58.0 | 57.5 ± 86.4 | 61.0 ± 88.9 | 61.1 ± 97.4 | 1.5 | .2 |
| GGO | 27.1 ± 45.4 | 42.8 ± 66.9 | 44.1 ± 61.8 | 57.5 ± 94.7 | 1.6 | .2 |
| Consolidation | 9.0 ± 16.8 | 14.7 ± 22.6 | 16.8 ± 33.9 | 3.5 ± 4.0 | 1.9 | .1 |

Abbreviations: BMI, body mass index; GGO, ground-glass opacity.

*Represents a significant difference between COVID-19 patients with normal BMI and obese COVID-19 patients (P < 0.05, Bonferroni-corrected).
However, the trajectory of COVID-19 development is unclear, especially in obese patients. Chest computed tomography (CT) is a valuable method of monitoring COVID-19 severity, and provides an opportunity to explore this question. Artificial intelligence (AI) has been successfully applied to chest CT segmentation with high repeatability. In the present study, we used AI-supported CT lesion quantification to evaluate the daily accumulation of lung lesions and aimed to determine the period during which pneumonia developed fastest in obese patients.

We enrolled 231 patients with laboratory-confirmed COVID-19, who were admitted to nine designated hospitals for treatment between January 20 and March 11, 2020 (Appendix S1). Clinical information, chest CT and laboratory data were collected (Appendix S2). As previously, we defined underweight, normal, overweight and obese as a body mass index (BMI) <18.5, 18.5–22.9, 23.0–26.9 and ≥27 kg/m², respectively. Based on AI segmentation, we estimated the volume of total pneumonia lesions, ground-glass opacity (GGO) and consolidation, and calculated accumulated pneumonia lesions (mm³) and volume changes (mm³/d; Appendix S3). We used ANOVA to examine the differences in clinical information, laboratory and pneumonia lesions among groups, followed by post hoc t-tests (P < 0.05). We then explored the relationships between BMI, pneumonia lesions and laboratory results based on Pearson correlation (P < 0.05).

Obese patients had greater total lesion and GGO volume in the whole/bilateral superior/right inferior lung lobe and greater consolidation in the right superior lung than patients with normal BMI (P < 0.05; Table 1). Results remained mostly unchanged after correction for lung volume (Appendix S4), personal disease history and demographics (Appendix S5). However, only trends were observed for greater pneumonia lesion volume in overweight and underweight patients compared with those with normal BMI (P > 0.05). Additionally, BMI was correlated with total lesions, GGO and consolidation (r = 0.52, 0.51 and 0.44, respectively; P < 0.001). Regarding laboratory results, obese patients had higher C-reactive protein levels than patients with normal BMI (P < 0.05). Across groups, C-reactive protein was related to total lesions, GGO and consolidation (r = 0.52, 0.51 and 0.44, respectively; P < 0.001). Longitudinally, across groups, total lesion volume increased during the first 10 days after symptom onset (peak: 276.74 mm³) then gradually decreased; lesions accumulated during the first 10 days, while the progression rate steadily
decreased (Figure 1A,B). In obese patients, lesion volume peaked at 10 days (550.16 mm\(^3\)), and there was rapid lesion growth before day 7 (peak: 38.11 mm\(^3\)/d). By contrast, overweight patients and those with normal BMI experienced decelerating and slower lesion growth, with the peak lesion and lesion accumulation rate being lower than in obese patients (Figure 1C,D).

Conclusively, obese COVID-19 patients had more diffuse pneumo-nia lesions than those with normal BMI, with lesions extending from inferior to superior lobes.\(^{17-19}\) The right inferior lobe was most often involved, which may be attributed to the anatomical features of the right inferior lobar bronchus (straighter and steeper than the others). Regarding pneumonia features, GGO predominates the lesions, suggesting that the pulmonary interstitium is susceptible to COVID-19 virus invasion.\(^{8,17,18,20}\) Longitudinally, obese patients had a more severe disease course than patients with normal BMI, which is consistent with evidence that these patients had worse disease prognosis.\(^\text{21}\) Interestingly, studies have also reported that obesity is associated with worse prognosis in other respiratory viruses (eg, H1N1 influenza).\(^{22-25}\) We thus inferred that the obesity effects on viral pneumonia were non-specific. Notably, one report contradicted our results and showed that the BMI was not closely associated with the severity of COVID-19.\(^\text{26}\) Different ethnic groups and disease stages may account for the discrepancy between the two studies.\(^\text{27}\)

The C-reactive protein results of obese patients with COVID-19 partly supported the hypothesis that an aggravated inflammation process is a critical element in disease progression in obese patients.\(^{28-30}\) Other potential mechanisms include the possibility that COVID-19 virus has a high affinity for human ACE2 (receptors highly expressed in adipose tissue), and obesity-related comorbidities may aggravate pneumonia.\(^{31-35}\) Additionally, underweight COVID-19 patients had similar lesion volumes to overweight patients. Both underweight and overweight COVID-19 patients had increased trend of lesion volumes than normal BMI patients (p>0.05). An adipose tissue imbalance-related immune response in underweight patients may account for these unexpected results. However, the small sample of underweight patients inevitably weakens this finding; further studies are needed. Another limitation of this work is that heterogeneous CT parameters may have had an impact on lesion segmentation.

The Ethics Committee of the Second Affiliated Hospital of the Zhejiang University of Medical School approved our study. All patients provided written informed consent.

ACKNOWLEDGMENTS

This work was supported by the Zhejiang University special scientific research fund for COVID-19 prevention and control (no: 2020XGZX036).

CONFLICTS OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

X. L., Y. J. and M. Z. contributed to the writing of the manuscript and study design. Z.S., Q.W. and P. H. contributed to critical data collection and analysis of the study. B. L. and L. S. contributed to the automated segmentation of chest CT. H. Z., H. Z., Y. L., Y. G., S. H., W. J., Y. L., J.M., L.M., X.W., M.W., M.S. contributed to enrolling patients with COVID-19.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14194.

DATA AVAILABILITY STATEMENT

The database used and analyzed in the present study is available from the corresponding author on reasonable request.

Xiao Luo MD\(^1\) 
Yeerfan Jiaerken MD\(^1\) 
Zhujing Shen MD\(^1\) 
Qiyuan Wang MD\(^1\) 
Bo Liu PhD\(^2,3\) 
Haisheng Zhou MD\(^4\) 
Hanpeng Zheng MD\(^4\) 
Yongchou Li MD\(^5\) 
Yuantong Gao MD\(^5\) 
Susu He MD\(^6\) 
Wenbin Ji MD\(^7\) 
Yongqiang Liu MD\(^8\) 
Jianbing Ma MD\(^9\) 
Longyun Mao MD\(^10\) 
Xiangming Wang MD\(^10\) 
Meihao Wang MD\(^11\) 
Miaoguang Su MD\(^12\) 
Peiyu Huang PhD\(^1\) 
Lei Shi MD\(^2\) 
Minnming Zhang MD\(^1\) 

\(^1\)Department of Radiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
\(^2\)Shanghai Key Laboratory of Artificial Intelligence for Medical Image and Knowledge Graph, Shanghai, China
\(^3\)Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, China
\(^4\)Department of Radiology, Yueqing People’s Hospital, Wenzhou, China
\(^5\)Department of Radiology, Ruian People’s Hospital, Third Affiliated Hospital of Wenzhou Medical University, Rui’an, China
\(^6\)Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, China
\(^7\)Department of Radiology, Taizhou Hospital of Zhejiang Province, Taizhou, China
\(^8\)Department of Radiology, Kecheng People’s Hospital, Quzhou, China
\(^9\)Department of Radiology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, China
As joint first authors, Xiao Luo and Yeerfan Jiaerken contributed equally to this work.

ORCID
Xiao Luo MD ▪ https://orcid.org/0000-0003-1743-7842
Minming Zhang MD ▪ https://orcid.org/0000-0003-0145-7558

REFERENCES
1. Vas P, Hopkins D, Feher M, Rubino F, Martin M. Diabetes, obesity and COVID-19: A complex interplay. Diabetes Obes Metab. 2020;22(10):1892-1896.
2. Lijtter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896-897.
3. Bornstein SR, Dalan R, Hopkins D, Minjironge G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020;16(6):297-298.
4. Bhatraju PK, Ghossemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-2022.
5. Gao F, Zheng KI, Wang X-B, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43:e72-e74.
6. Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43:1392-1398.
7. A1 T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology. 2020;296(2):E32-E40.
8. Ng M-Y, Lee EY, Yang J, et al. Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiolgy. 2020;2(1):e200034.
9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
10. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295(1):202-207.
11. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;295(3):715-721.
12. Zhao W, Zhong X, Xie X, Yu Q, Liu J. CT scans of patients with 2019 novel coronavirus (COVID-19) pneumonia. Theranostics. 2020;10(10):4606-4613.
13. Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10(12):5613-5622.
14. Who EC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157.
15. Wang S, Zhou M, Liu Z, et al. Central focused convolutional neural networks: Developing a data-driven model for lung nodule segmenta- tion. Med Image Anal. 2017;40:172-183.
16. Ji M, Yuan L, Shen W, et al. A predictive model for disease progression in non-severe illness patients with Corona Virus Disease 2019. Eur Respir J. 2020;56:2001234.
17. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. Am J Roentgenol. 2020;214(6):1287-1294.
18. Wong HYF, Lam HYS, AH-T F, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2020;296(2):E72-E78.
19. Yu Q, Wang Y, Huang S, et al. Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients. Theranostics. 2020;10(12):5641-5648.
20. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiol- ogy. 2020;295(3):200463.
21. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. 2020;28(7):1200-1204.
22. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011;52(3):301-312.
23. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A (H1N1) disease. PLoS One. 2010;5(3):e9694.
24. Badawi A, Ryo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-133.
25. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA. 2009;302(17):1896-1902.
26. ICNARC. https://www.icnarc.org/About/Latest-News/2020/04/04/ Report-on-2249-patients-critically-ill-with-Covid-19. Accessed 9 April 2020.
27. Raziel C, Zaccardi F, Davies MJ, Khunti K, Yates T. Body mass index and risk of COVID-19 across ethnic groups: analysis of UK Biobank study. Diabetes Obes Metab. 2020;22(10):1953-1954.
28. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
29. Fang G, Zheng KI, Yan Q-Q, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Transl Hepatol. 2020;8(1):18-24.
30. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection in non-severe illness patients with Corona Virus Disease 2019. Diabetes Obes Metab. 2020;22(10):1955-1957.
31. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. 2020;28(7):1200-1204.
32. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011;52(3):301-312.
33. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A (H1N1) disease. PLoS One. 2010;5(3):e9694.
34. Badawi A, Ryo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-133.
35. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA. 2009;302(17):1896-1902.
36. ICNARC. https://www.icnarc.org/About/Latest-News/2020/04/04/ Report-on-2249-patients-critically-ill-with-Covid-19. Accessed 9 April 2020.
37. Raziel C, Zaccardi F, Davies MJ, Khunti K, Yates T. Body mass index and risk of COVID-19 across ethnic groups: analysis of UK Biobank study. Diabetes Obes Metab. 2020;22(10):1953-1954.